Form 4 for ABBV AbbVie
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-16 · accession 0001415889-23-002945 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-21 | 2023-02-17 | ABBV | SALEKI-GERHARDT AZITA | EVP, Ops | S - Sale+OE | $149.53 | -25.0K | 233.2K | -10% | -$3.74M |
| D | 2023-02-21 | 2023-02-17 | ABBV | SALEKI-GERHARDT AZITA | EVP, Ops | M - OptEx | $51.42 | +25.0K | 258.2K | +11% | +$1.29M |
| DM | 2023-02-21 | 2023-02-16 | ABBV | SALEKI-GERHARDT AZITA | EVP, Ops | A - Grant | $0.00 | +75.3K | 206.0K | +58% | $0 |
| D | 2023-02-21 | 2023-02-17 | ABBV | SALEKI-GERHARDT AZITA | EVP, Ops | M - OptEx | $51.42 | -25.0K | 0 | -100% | -$1.29M |
| D | 2023-02-21 | 2023-02-16 | ABBV | SALEKI-GERHARDT AZITA | EVP, Ops | A - Grant | $0.00 | +23.0K | 23.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2023-02-17 | S | D | 14,246 | $149.13 | 243,962 | D | — | — | (F5) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.69 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock, $0.01 par value | 2023-02-17 | M | A | 25,000 | $51.42 | 258,208 | D | — | — | |
| 3 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 7,380 | $0.00 | 233,208 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 4 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 8,560 | $0.00 | 225,828 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 5 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 11,229 | $0.00 | 217,268 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 6 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 48,127 | $0.00 | 206,039 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 7 | Common | Common Stock, $0.01 par value | 2023-02-17 | S | D | 10,754 | $150.05 | 233,208 | D | — | — | (F6) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.71 to $150.05 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8 | Derivative | Option (Right to Buy) | 2023-02-17 | M | D | 25,000 | $51.42 | 0 | D | $51.42 · 2015-02-20 to 2024-02-19 | 25,000 Common Stock | (F10) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| 9 | Derivative | Option (Right to Buy) | 2023-02-16 | A | A | 22,957 | $0.00 | 22,957 | D | $149.62 · 2024-02-16 to 2033-02-15 | 22,957 Common Stock | (F9) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,653 on February 16, 2024, 7,652 on February 16, 2025, and 7,652 on February 16, 2026. |